Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline

Stock Track

02-27

Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.

Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.

Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1197508058"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197508058\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1197508058?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197508058","market":"hk","top_or_hot":-1,"title":"Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline","media":"Stock Track","content":"<p>Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.</p>\n\n<p>Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.</p>\n\n<p>Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-27 23:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.</p>\n\n<p>Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.</p>\n\n<p>Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SDGR","symbol_name":"Schrodinger Inc.","start_time":0,"source_url":"","article_id":"1197508058","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197508058","pubTimestamp":1740668778,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Schrodinger Inc.  shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SDGR":"Schrodinger Inc."},"translate_title":"由于强劲的软件增长和光明的前景超过了收入下降，Schrodinger股价飙升5.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SDGR":1},"content_text":"Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.\nDespite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.\nAnalysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}